Blinatumomab - Biologic Drug Details
✉ Email this page to a colleague
Summary for blinatumomab
| Tradenames: | 1 |
| High Confidence Patents: | 4 |
| Applicants: | 1 |
| BLAs: | 1 |
| Suppliers: see list | 1 |
| Recent Clinical Trials: | See clinical trials for blinatumomab |
Recent Clinical Trials for blinatumomab
Identify potential brand extensions & biosimilar entrants
| Sponsor | Phase |
|---|---|
| Zhejiang University | Phase 1 |
| Sichuan University | Phase 2 |
| Ho Joon Im | Phase 2 |
Note on Biologic Patents
Matching patents to biologic drugs is far more complicated than for small-molecule drugs.
DrugPatentWatch employs three methods to identify biologic patents:
- Brand-side disclosures in response to biosimilar applications
- General brand-side disclosures
- Patents from broad patent text search
These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.
These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
1) High Certainty: US Patents for blinatumomab Derived from Brand-Side Litigation
No patents found based on brand-side litigation
2) High Certainty: US Patents for blinatumomab Derived from Company Disclosures
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Patent No. | Estimated Patent Expiration | Source |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | BLINCYTO | blinatumomab | For Injection | 125557 | ⤷ Subscribe | 2024-11-26 | Company disclosures |
| Amgen Inc. | BLINCYTO | blinatumomab | For Injection | 125557 | ⤷ Subscribe | 2032-04-30 | Company disclosures |
| Amgen Inc. | BLINCYTO | blinatumomab | For Injection | 125557 | ⤷ Subscribe | 2018-04-21 | Company disclosures |
| Amgen Inc. | BLINCYTO | blinatumomab | For Injection | 125557 | ⤷ Subscribe | 2018-04-21 | Company disclosures |
| Amgen Inc. | BLINCYTO | blinatumomab | For Injection | 125557 | ⤷ Subscribe | 2025-12-16 | Company disclosures |
| Amgen Inc. | BLINCYTO | blinatumomab | For Injection | 125557 | ⤷ Subscribe | 2029-10-27 | Company disclosures |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Patent No. | >Estimated Patent Expiration | >Source |
3) Low Certainty: US Patents for blinatumomab Derived from Patent Text Search
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Patent No. | Estimated Patent Expiration | Source |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | BLINCYTO | blinatumomab | For Injection | 125557 | ⤷ Subscribe | 2033-02-08 | Patent claims search |
| Amgen Inc. | BLINCYTO | blinatumomab | For Injection | 125557 | ⤷ Subscribe | 2035-05-04 | Patent claims search |
| Amgen Inc. | BLINCYTO | blinatumomab | For Injection | 125557 | ⤷ Subscribe | 2032-02-15 | Patent claims search |
| Amgen Inc. | BLINCYTO | blinatumomab | For Injection | 125557 | ⤷ Subscribe | 2036-06-30 | Patent claims search |
| Amgen Inc. | BLINCYTO | blinatumomab | For Injection | 125557 | ⤷ Subscribe | 2035-10-05 | Patent claims search |
| Amgen Inc. | BLINCYTO | blinatumomab | For Injection | 125557 | ⤷ Subscribe | 2035-07-15 | Patent claims search |
| Amgen Inc. | BLINCYTO | blinatumomab | For Injection | 125557 | ⤷ Subscribe | 2035-07-15 | Patent claims search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Patent No. | >Estimated Patent Expiration | >Source |
International Patents for blinatumomab
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2011051307 | ⤷ Subscribe |
| China | 1299410 | ⤷ Subscribe |
| Canada | 2326389 | ⤷ Subscribe |
| Poland | 199747 | ⤷ Subscribe |
| China | 1302103 | ⤷ Subscribe |
| Brazil | PI9909860 | ⤷ Subscribe |
| South Africa | 200806095 | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for blinatumomab
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 16C1000 | France | ⤷ Subscribe | PRODUCT NAME: BLINATUMOMAB; REGISTRATION NO/DATE: EU/1/15/1047 20151125 |
| 1690016-9 | Sweden | ⤷ Subscribe | PRODUCT NAME: BLINATUMOMAB; REG. NO/DATE: EU/1/15/1047 20151123 |
| CR 2016 00020 | Denmark | ⤷ Subscribe | PRODUCT NAME: BLINATUMOMAB; REG. NO/DATE: EU/1/15/1047 20151125 |
| 300807 | Netherlands | ⤷ Subscribe | PRODUCT NAME: BLINATUMOMAB; REGISTRATION NO/DATE: EU/1/15/1047 20151125 |
| 259 5010-2016 | Slovakia | ⤷ Subscribe | PRODUCT NAME: BLINATUMOMAB; REGISTRATION NO/DATE: EU/1/15/1047 20151125 |
| CA 2016 00020 | Denmark | ⤷ Subscribe | PRODUCT NAME: BLINATUMOMAB; REG. NO/DATE: EU/1/15/1047 20151125 |
| C20160016 00182 | Estonia | ⤷ Subscribe | PRODUCT NAME: BLINATUMOMAB;REG NO/DATE: EU/1/15/1047 25.11.2015 |
| >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
